SAGE Therapeutics (NASDAQ:SAGE) Rating Lowered to Neutral at LADENBURG THALM/SH SH

SAGE Therapeutics (NASDAQ:SAGE) was downgraded by research analysts at LADENBURG THALM/SH SH from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Friday, Marketbeat reports.

SAGE has been the subject of a number of other reports. Goldman Sachs Group dropped their price objective on shares of SAGE Therapeutics from $227.00 to $263.00 in a research note on Thursday. Wedbush decreased their target price on shares of SAGE Therapeutics from $203.00 to $90.00 and set an “outperform” rating on the stock in a research report on Thursday. Morgan Stanley lowered their price target on shares of SAGE Therapeutics from $217.00 to $125.00 and set an “overweight” rating for the company in a report on Friday. Svb Leerink raised shares of SAGE Therapeutics from an “underperform” rating to a “market perform” rating in a report on Friday. Finally, Leerink Swann upgraded SAGE Therapeutics from an “underperform” rating to a “market perform” rating and set a $63.00 price target for the company in a research report on Friday. One analyst has rated the stock with a sell rating, six have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. SAGE Therapeutics has an average rating of “Buy” and an average price target of $128.81.

NASDAQ SAGE opened at $64.46 on Friday. The stock has a 50 day moving average price of $142.30 and a 200-day moving average price of $160.81. SAGE Therapeutics has a one year low of $56.50 and a one year high of $193.56. The company has a debt-to-equity ratio of 0.03, a quick ratio of 12.67 and a current ratio of 12.67. The company has a market capitalization of $3.34 billion, a P/E ratio of -7.98 and a beta of 2.52.

SAGE Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($3.48) earnings per share for the quarter, missing the consensus estimate of ($3.41) by ($0.07). The business had revenue of $3.57 million during the quarter, compared to the consensus estimate of $2.52 million. SAGE Therapeutics had a negative return on equity of 60.00% and a negative net margin of 12,931.34%. The company’s revenue for the quarter was up 35600.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($2.63) EPS. As a group, equities analysts predict that SAGE Therapeutics will post -13.77 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. raised its position in SAGE Therapeutics by 197.2% in the 2nd quarter. Invesco Ltd. now owns 2,021,964 shares of the biopharmaceutical company’s stock worth $370,201,000 after purchasing an additional 1,341,720 shares during the period. Nuveen Asset Management LLC bought a new stake in SAGE Therapeutics in the second quarter worth about $113,776,000. Jennison Associates LLC boosted its position in shares of SAGE Therapeutics by 25.4% during the second quarter. Jennison Associates LLC now owns 2,953,913 shares of the biopharmaceutical company’s stock valued at $540,832,000 after buying an additional 598,299 shares during the period. Janus Henderson Group PLC boosted its position in shares of SAGE Therapeutics by 12.3% during the second quarter. Janus Henderson Group PLC now owns 1,873,408 shares of the biopharmaceutical company’s stock valued at $343,002,000 after buying an additional 204,779 shares during the period. Finally, State Street Corp grew its stake in shares of SAGE Therapeutics by 8.8% during the third quarter. State Street Corp now owns 1,039,599 shares of the biopharmaceutical company’s stock valued at $145,845,000 after buying an additional 84,138 shares during the last quarter.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Featured Story: Why is the ex-dividend date different from the record date?

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.